Literature DB >> 22960020

Thirty-day vein remodeling is predictive of midterm graft patency after lower extremity bypass.

Warren J Gasper1, Christopher D Owens, Ji Min Kim, Nancy Hills, Michael Belkin, Mark A Creager, Michael S Conte.   

Abstract

OBJECTIVE: Successful adaptation of a vein graft to an arterial environment is incompletely understood. We sought to investigate whether early vein graft remodeling is predictive of subsequent patency.
METHODS: A prospective longitudinal study was conducted of 67 patients undergoing lower extremity bypass with autogenous vein between February 2004 and April 2008. Preoperative blood samples were drawn for biomarkers. During the bypass operation, a 5-cm index segment of the graft was registered for serial lumen diameter measurements at 0, 1, 3, 6, 9, and 12 months using duplex ultrasound imaging. The imaging substudy analysis included patients with at least two ultrasound assessments.
RESULTS: Patients (55% male) were a median age of 70 years (interquartile range [IQR], 59-76 years), 40% had diabetes mellitus, 49% had critical limb ischemia, 75% were taking a statin, and 91% were taking an antiplatelet medication. Median follow-up was 32 months (IQR, 15-47 months). The median baseline high-sensitivity C-reactive protein level (hsCRP) was 3.2 mg/L (IQR, 1.4-9.7 mg/L). The average intraoperative, postimplantation vein lumen diameter was 3.9±1.0 mm, increasing to 4.7±1.1 mm at 1 month, an average 24%±27% change per patient. By 3 months, the average lumen diameter was 5.1±1.6 mm, with little subsequent change observed to 12 months. Nonwhite race, baseline hsCRP ≥5 mg/L, statin use, and initial lumen diameter were significantly associated with early (0- to 1-month) vein remodeling in a multivariable regression model. The primary patency rate for the cohort was 60%±6.3% at 2 years. Initial lumen diameter of the index segment was not associated with primary patency, whereas larger lumen diameter achieved at 1 month (≥5.1 mm) was positively associated with primary patency (log-rank, P=.03). Early (30-day) remodeling behavior was used to divide patients into "poor remodelers" (<-5% lumen diameter change, n=6), "modest remodelers" (-5% to 25% change, n=29), and "robust remodelers" (>+25% change, n=30). Early remodeling category was significantly associated with primary patency rate at 2 years (log-rank, P=.02). A multivariable Cox proportional hazards model showed that modest remodelers (hazard ratio, 3.9; 95% confidence interval, 1.02-15; P=.04) and poor remodelers (hazard ratio, 13; 95% confidence interval; P=.008) had significantly higher hazard ratios for graft failure than robust early remodelers.
CONCLUSIONS: Early remodeling of the arterialized vein appears to predict midterm bypass graft patency. In addition to baseline diameter, race, inflammation, hsCRP, and statin use are associated with early adaptive remodeling, but the mechanisms for these observations are not understood.
Copyright © 2013 Society for Vascular Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22960020      PMCID: PMC3529790          DOI: 10.1016/j.jvs.2012.06.098

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  34 in total

1.  Lumen loss in the first year in saphenous vein grafts is predominantly a result of negative remodeling of the whole vessel rather than a result of changes in wall thickness.

Authors:  George T Lau; Lloyd J Ridley; Paul G Bannon; Louise A Wong; Joseph Trieu; David B Brieger; Harry C Lowe; Ben S Freedman; Leonard Kritharides
Journal:  Circulation       Date:  2006-07-04       Impact factor: 29.690

2.  Early biomechanical changes in lower extremity vein grafts--distinct temporal phases of remodeling and wall stiffness.

Authors:  Christopher D Owens; Nicole Wake; Jeffrey G Jacot; Marie Gerhard-Herman; Peter Gaccione; Michael Belkin; Mark A Creager; Michael S Conte
Journal:  J Vasc Surg       Date:  2006-08-22       Impact factor: 4.268

3.  The effect of novel cardiovascular risk factors on the ethnic-specific odds for peripheral arterial disease in the Multi-Ethnic Study of Atherosclerosis (MESA).

Authors:  Matthew A Allison; Michael H Criqui; Robyn L McClelland; JoAnn M Scott; Mary M McDermott; Kiang Liu; Aaron R Folsom; Alain G Bertoni; A Richey Sharrett; Shunichi Homma; Sujata Kori
Journal:  J Am Coll Cardiol       Date:  2006-08-28       Impact factor: 24.094

4.  Comparative analysis of autogenous infrainguinal bypass grafts in African Americans and Caucasians: the association of race with graft function and limb salvage.

Authors:  David K Chew; Louis L Nguyen; Christopher D Owens; Michael S Conte; Anthony D Whittemore; Edwin C Gravereaux; Mathew T Menard; Michael Belkin
Journal:  J Vasc Surg       Date:  2005-10       Impact factor: 4.268

5.  Serum C-reactive protein response to percutaneous coronary intervention in patients with unstable or stable angina pectoris is associated with the risk of clinical restenosis.

Authors:  Nawsad Saleh; Per Tornvall
Journal:  Atherosclerosis       Date:  2006-11-28       Impact factor: 5.162

6.  Elevated C-reactive protein levels are associated with postoperative events in patients undergoing lower extremity vein bypass surgery.

Authors:  Christopher D Owens; Paul M Ridker; Michael Belkin; Allen D Hamdan; Frank Pomposelli; Frank Logerfo; Mark A Creager; Michael S Conte
Journal:  J Vasc Surg       Date:  2006-11-21       Impact factor: 4.268

7.  Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery.

Authors:  Michael S Conte; Dennis F Bandyk; Alexander W Clowes; Gregory L Moneta; Lynn Seely; Todd J Lorenz; Hamid Namini; Allen D Hamdan; Sean P Roddy; Michael Belkin; Scott A Berceli; Richard J DeMasi; Russell H Samson; Scott S Berman
Journal:  J Vasc Surg       Date:  2006-04       Impact factor: 4.268

8.  C-reactive protein in peripheral arterial disease: relation to severity of the disease and to future cardiovascular events.

Authors:  Tryfon Vainas; Frank R M Stassen; Rick de Graaf; Eric L L Twiss; Selma B Herngreen; Rob J Th J Welten; Luc H J M van den Akker; Marja P van Dieijen-Visser; Cathrien A Bruggeman; Peter J E H M Kitslaar
Journal:  J Vasc Surg       Date:  2005-08       Impact factor: 4.268

9.  Technical factors affecting autogenous vein graft failure: observations from a large multicenter trial.

Authors:  Andres Schanzer; Nathanael Hevelone; Christopher D Owens; Michael Belkin; Dennis F Bandyk; Alexander W Clowes; Gregory L Moneta; Michael S Conte
Journal:  J Vasc Surg       Date:  2007-12       Impact factor: 4.268

10.  Factors associated with early failure of infrainguinal lower extremity arterial bypass.

Authors:  Niten Singh; Anton N Sidawy; Kent J DeZee; Richard F Neville; Cameron Akbari; William Henderson
Journal:  J Vasc Surg       Date:  2008-03       Impact factor: 4.268

View more
  16 in total

Review 1.  Future research directions to improve fistula maturation and reduce access failure.

Authors:  Haidi Hu; Sandeep Patel; Jesse J Hanisch; Jeans M Santana; Takuya Hashimoto; Hualong Bai; Tambudzai Kudze; Trenton R Foster; Jianming Guo; Bogdan Yatsula; Janice Tsui; Alan Dardik
Journal:  Semin Vasc Surg       Date:  2016-08-26       Impact factor: 1.000

2.  Scavenger receptor class A member 5 (SCARA5) and suprabasin (SBSN) are hub genes of coexpression network modules associated with peripheral vein graft patency.

Authors:  Richard D Kenagy; Mete Civelek; Shinsuke Kikuchi; Lihua Chen; Anthony Grieff; Michael Sobel; Aldons J Lusis; Alexander W Clowes
Journal:  J Vasc Surg       Date:  2015-04-30       Impact factor: 4.268

3.  Surgical marking pen dye inhibits saphenous vein cell proliferation and migration in saphenous vein graft tissue.

Authors:  Shinsuke Kikuchi; Richard D Kenagy; Lu Gao; Thomas N Wight; Nobuyoshi Azuma; Michael Sobel; Alexander W Clowes
Journal:  J Vasc Surg       Date:  2015-04-30       Impact factor: 4.268

4.  A single nucleotide polymorphism of cyclin-dependent kinase inhibitor 1B (p27Kip1) associated with human vein graft failure affects growth of human venous adventitial cells but not smooth muscle cells.

Authors:  Richard D Kenagy; Shinsuke Kikuchi; Lihua Chen; Errol S Wijelath; Andrew B Stergachis; John Stamatoyannopoulos; Gale L Tang; Alexander W Clowes; Michael Sobel
Journal:  J Vasc Surg       Date:  2017-05-16       Impact factor: 4.268

Review 5.  Vein graft adaptation and fistula maturation in the arterial environment.

Authors:  Daniel Y Lu; Elizabeth Y Chen; Daniel J Wong; Kota Yamamoto; Clinton D Protack; Willis T Williams; Roland Assi; Michael R Hall; Nirvana Sadaghianloo; Alan Dardik
Journal:  J Surg Res       Date:  2014-01-30       Impact factor: 2.192

Review 6.  Vein graft failure.

Authors:  Christopher D Owens; Warren J Gasper; Amreen S Rahman; Michael S Conte
Journal:  J Vasc Surg       Date:  2013-10-03       Impact factor: 4.268

Review 7.  Vein graft failure: from pathophysiology to clinical outcomes.

Authors:  Margreet R de Vries; Karin H Simons; J Wouter Jukema; Jerry Braun; Paul H A Quax
Journal:  Nat Rev Cardiol       Date:  2016-05-19       Impact factor: 32.419

8.  A single nucleotide polymorphism in the p27(Kip1) gene is associated with primary patency of lower extremity vein bypass grafts.

Authors:  Michael S Conte; Christopher D Owens; Michael Belkin; Mark A Creager; Karen L Edwards; Warren J Gasper; Richard D Kenagy; Renee C LeBoeuf; Michael Sobel; Alexander Clowes
Journal:  J Vasc Surg       Date:  2013-01-09       Impact factor: 4.268

9.  Anti-phosphorylcholine IgM, an Anti-inflammatory Mediator, Predicts Peripheral Vein Graft Failure: A Prospective Observational Study.

Authors:  Michael Sobel; Mayumi Yagi; Katherine Moreno; Ted R Kohler; Gale L Tang; Errol S Wijelath; Julieann Marshall; Richard D Kenagy
Journal:  Eur J Vasc Endovasc Surg       Date:  2018-10-19       Impact factor: 7.069

Review 10.  Resolution of vascular injury: Specialized lipid mediators and their evolving therapeutic implications.

Authors:  Bian Wu; Giorgio Mottola; Melinda Schaller; Gilbert R Upchurch; Michael S Conte
Journal:  Mol Aspects Med       Date:  2017-08-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.